Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumito ABNGM:LUMITO +10.00%18 Gross Margin % is 0.00% as of Mar. 2026. GuruFocus rates NGM:LUMITO with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, Lumito AB ranks better than 98.96% on this metric.
The historical rank and industry rank for Lumito AB's Gross Margin % or its related term are showing as below:
NGM:LUMITO'
s Gross Margin % Range Over the Past 10 Years
Min: 152.56 Med: 4170.71 Max: 4170.71
Current: 152.56
During the past 9 years, the highestGross Margin % of Lumito AB was 4170.71%. The lowest was 152.56%. And the median was 4170.71%.
NGM:LUMITO's Gross Margin % is ranked better than 98.96% of 193
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.31
vs NGM:LUMITO: 152.56
Lumito AB had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Lumito AB was 0.00% per year.
Lumito AB (NGM:LUMITO) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Lumito AB had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Lumito AB Gross Margin % Related Terms
Lumito AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Lumito AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:LUMITO vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Lumito AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumito AB Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lumito AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Lumito AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Lumito AB (NGM:LUMITO) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Lumito AB and its competitors. Over the past decade, Lumito AB's Gross Margin % has ranged from 152.56 to 4,170.71. According to the industry distribution chart, Lumito AB ranks #2 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 1%.
Is Lumito AB's Gross Margin % too high?
Lumito AB's current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 152.56 to a high of 4,170.71. Based on the distribution chart, Lumito AB ranks #2 out of 193 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Lumito AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Lumito AB's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumito AB ranks #2 out of 193 companies for Gross Margin %. This places Lumito AB in the top 1% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 51.31. Historically, Lumito AB's own Gross Margin % has ranged from 152.56 to 4,170.71 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.31, based on 193 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Lumito AB and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumito AB's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumito AB stock overvalued right now?
Lumito AB (NGM:LUMITO) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Lumito AB's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Lumito AB (NGM:LUMITO), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lumito AB is a Swedish company that specializes in the medical research and development of imaging technology for use in digital pathology. It has developed the next-generation tissue analysis system, based on upconverting nanoparticles (UCNPs). Lumito SCIZYS is a cutting-edge, high-sensitivity system combining labeling and imaging technologies to locate and measure biomarkers in tissue samples. The company holds a broad patent portfolio of three patent families. Lumito's solution enables quantitative and objective assessment of tissue samples, addressing a multitude of challenges in drug development and academic research.
18GF Score
Get the complete analysis for NGM:LUMITO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:LUMITO has been successfully added to your 
